Stocks
Intra-Cellular Therapies (ITCI) EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -153.5 | -230.7 | -285.2 | -263.0 | -158.9 | -121.2 | ||
| Changes by years, y/y, % | -5% | +50% | +24% | -8% | -40% | -0.4% | |||
Intra-Cellular Therapies. EBITDA US GAAP, bln rub
Intra-Cellular Therapies. EBITDA US GAAP, changes, %
Intra-Cellular Therapies. EBITDA US GAAP, sum by quarters, bln rub
Intra-Cellular Therapies (ITCI) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA, bln rub | ? | -29.6 | -34.0 | -20.8 | -27.6 | -38.8 | -121.2 | |
| Changes by years, y/y, % | -47% | -28% | -57% | -42% | +31% | |||
| Changes by quarters, q/q, % | -37% | +15% | -39% | +33% | +41% | |||
